Order byBest matchMost fresh
Regeneron's 23andMe Steal - Smart Genetics Play That Won't Cure Near-Term Growth Pains
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.
Regeneron agrees to buy bankrupt 23andMe, promises ethical use of customers' DNA data
Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of customers' DNA data.
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a $256 million deal to boost its genetics-based drug discovery efforts.
MassDevice1d
Regeneron to acquire 23andMe for $256M, plans to continue consumer genetics services
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to close in Q3 2025
STAT1d
Regeneron makes another deal — This one about AI
Regeneron has been busy, with two health tech deals announced this week: One is about genetic data and one about AI. Both of them are about developing and selling drugs, really.
Explore more
Feedback